Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: Continue or stop?

Pancreatology

Volumn 12, Issue 2, 2012, Pages 162-169

  Ren, Fang ^a   Xu, Ying Chun ^a   Wang, Hong Xia ^a   Tang, Lei ^a   Ma, Yue ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adjuvant therapy; Meta analysis; Pancreatic adenocarcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; MITOMYCIN C; MITOXANTRONE; UFT;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 84862827664     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.02.002     Document Type: Article

References (33)

1. International Agency for research on cancer, World Health Organization. Globocan. Web site. World Health Organization, http://globocan.iarc.fr/; 2008 [accessed 15.7.10].
2. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324-9. (Pubitemid 36920145)
3. Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54: 385-7. (Pubitemid 40299095)
4. Zervos EE, Rosemurgy AS, Al-Saif O, Durkin AJ. Surgical management of earlystage pancreatic cancer. Cancer Control 2004;11:23-31. (Pubitemid 38595784)
5. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
6. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. (Pubitemid 15040883)
7. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77. (Pubitemid 46143304)
8. Lygidakis NJ, Spentzouris N, Theodoracopoulos M, Dedemadi G, Gemos K, Kyriakou A. Pancreatic resection for pancreatic carcinoma combined with neoand adjuvant locoregional targeting immuno-chemotherapyea prospective randomized study. Hepatogastroenterology 1998;45:396-403. (Pubitemid 28167657)
9. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 2008;38:227-9. (Pubitemid 351419748)
10. Märten A, Schmidt J, Ose J, Harig S, Abel U, Münter MW, et al. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding eventfree survival - CapRI-2. BMC Cancer 2009;9:160.
11. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-68. (Pubitemid 33117196)
12. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85. (Pubitemid 33101907)
13. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.
14. Yoshitomi H, Togawa A, Kimura F, Ito H, Shimizu H, Yoshidome H, et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008;113:2448-56.
15. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101:908-15.
16. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol 2006;36: 159-65.
17. Beger HG, Link KH, Gansauge F. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study. Hepatogastroenterology 1998;45:638-43. (Pubitemid 28321033)
18. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vatereresults of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29A:698-703. (Pubitemid 23077048)
19. Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 2002;236:806-13. (Pubitemid 35403236)
20. Lygidakis NJ, Berberabe AE, Spentzouris N, Dedemadi G, Kalligas T, Loukas G, et al. A prospective randomized study using adjuvant locoregional chemoimmunotherapy in combination with surgery for pancreatic carcinoma. Hepatogastroenterology 1998;45:2376-81. (Pubitemid 29055839)
21. Lygidakis NJ, Stringaris K. Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospective randomized study. Hepatogastroenterology 1996;43:671-80. (Pubitemid 26191295)
22. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013- 22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010;28:4450-6.
23. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26. (Pubitemid 351347058)
24. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
25. Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 2008;248:1031-41.
26. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82. discussion 782-774.
27. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985- 1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7. (Pubitemid 29307735)
28. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
29. Russ AJ, Weber SM, Rettammel RJ, Mahvi DM, Rikkers LF, Cho CS. Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol 2010;17:371-6.
30. Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008;248:1014-22.
31. Heinrich S, Pestalozzi B, Schafer M, Weber A, Bauerfeind P, Knuth A, et al. Prospective phase II trial on neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:2526-31.
32. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011;150:466-73.
33. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011;11:346.